

# William B Hillegass

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/683159/publications.pdf>

Version: 2024-02-01

26  
papers

25  
citations

2682572

2  
h-index

2272923

4  
g-index

26  
all docs

26  
docs citations

26  
times ranked

33  
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient preference: An important emerging factor in operator access site selection. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 25-26.	1.7	3
2	The many radial access learning curves. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 865-866.	1.7	3
3	Individualizing dual antiplatelet therapy duration: Prediction tools, genomics, and clinical judgment. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 38-38.	1.7	2
4	The promise of effective P2Y <sub>12</sub> platelet receptor pretreatment: Not crushed yet. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 251-252.	1.7	2
5	Embolic stroke of undetermined source and patent foramen ovale closure: Practice insights from meta-analysis?. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 1161-1162.	1.7	2
6	Costs of postoperative delirium with transcatheter aortic valve replacement: Improved yet still present. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 1137-1137.	1.7	2
7	Insulin-treated diabetes mellitus: An actionable risk factor and marker after percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 309-310.	1.7	2
8	Expanding the frame for valve-in-valve therapy in small bioprostheses: Encouraging signs for the road ahead. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 555-556.	1.7	1
9	Patent foramen ovale closure for cryptogenic stroke: Effective, but only in select patients. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 174-175.	1.7	1
10	Intravascular ultrasound of normal left main arteries: Insights for stent optimization and standardization. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 239-240.	1.7	1
11	Radial access and risk guided use of bivalirudin?. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1249-1250.	1.7	1
12	A step toward physiologically guided chronic limb-threatening ischemia intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 913-914.	1.7	1
13	Ticagrelor monotherapy: When is mono-antiplatelet therapy (MAPT) equivalent or better?. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1379-1380.	1.7	1
14	A step forward in predicting antegrade crossing success for infrapopliteal chronic total occlusions. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 756-757.	1.7	1
15	Prior probability of significant obstructive arterial disease in the contralateral lower extremity. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 307-308.	1.7	1
16	Covered stents favored in complex aortoiliac disease. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 938-939.	1.7	1
17	Length and pressure matter: Expediting evidence-based progress in femoropopliteal intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 1257-1258.	1.7	0
18	Long-term survival prospects of patients undergoing percutaneous coronary intervention: Envisioning the future. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 696-696.	1.7	0

#	ARTICLE	IF	CITATIONS
19	Surgical aortic valve replacement and transcatheter aortic valve implantation for severe aortic stenosis: Equipoise remains a tenable assumption. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 431-432.	1.7	0
20	Clopidogrel pretreatment may reduce early acquired thrombocytopenia after transcatheter aortic valve replacement (TAVR). <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 818-819.	1.7	0
21	Safety and efficacy of paclitaxel drug-coated balloon treatment of femoropopliteal claudicants: Data and analytic methods matter. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1100-1101.	1.7	0
22	Everolimus eluting bioresorbable vascular scaffolds for infrapopliteal critical limb ischemia: Moving beyond grasping at metal straws. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 150-151.	1.7	0
23	Antiplatelet therapy regimen and duration after percutaneous coronary intervention: Combining prediction scores with clinical judgment. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 579-580.	1.7	0
24	Genotype-guided antiplatelet therapy for acute coronary syndrome percutaneous coronary intervention patients: A new standard of care?. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 795-796.	1.7	0
25	Critical limb ischemia in the end stage renal disease patient: Some next steps. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 308-309.	1.7	0
26	Successfully treating the common femoral artery "no go zone" with directional atherectomy plus antirestenotic therapy (DAART). <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 1317-1318.	1.7	0